62
Table 2 (continued)
Compound
Pharmaceutical
activity
Optimal deep eutectic
solvent composition(s)
Therapeutic
deep
eutectic
solvents
References
Caffeine
Model drug
CH:GLN 1:1; CH:PHE
1:1
Santos de
Almeida et al.
(2017)
Carthamin
Antioxidant
X:CC:W 1:2:3
Dai et al.
(2013, 2015)
Cefadroxil
Antibiotic
C:GE 1:2
Zakrewsky
et al. (2015,
2016b)
Ceftazidime
Antibiotic
C:GE 1:2
Zakrewsky
et al. (2015,
2016b)
Cinnamic acid
Antioxidant and
antimicrobial
PD:CC:W 1:1:1
Dai et al.
(2013)
Clavulanic acid
Antibiotic
B:U 1:1.5
Olivares et al.
(2018)
Chlorambucil
Anticancer
Conjugate with
dimethylaminopropanol:
1,4, butanediol
✓
Pradeepkumar
et al. (2018)
Coenzyme Q
Antioxidant
Coenzyme Q:LAU 2:1
✓
Tarate and
Bansal (2015)
methoxy-2,2dimethyl- 1(2H)benzopyran (CR-6)
Antioxidant
PD:CC:W 1:1:1
Durand et al.
(2017)
methoxy-2,2dimethyl- 1(2H)benzopyran
palmitate (CR-6
palmitate)
Antioxidant
PD:CC:W 1:1:1
Durand et al.
(2017)
Curcumin
Antimicrobial
and
photosensitizer
G:S 1:1; MEA:CC 1:3
Wikene et al.
(2015a)
Danazol
Gonadotrophin
inhibitor
MOA:CC 1:1
Morrison et al.
(2009)
Decyl rosmarinate Antioxidant
PD:CC:W 1:1:1
Durand et al.
(2017)
Erythritol
Antibiotic
ZC:drug 1:3; B:drug 2:1
✓
Lim et al.
(2018)
Ethambutol
Antibiotic
CA:ethambutol:W 2:1:10
✓
Santos et al.
(2019)
(continued)
C.-H. Nguyen et al.